You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The grant is specifically intended to support the development of noninvasive, rapid tests that can be used at the point of care in developing country settings.
The funding builds on more than $1.7 million already awarded to the firm, which is building a diagnostic for characterizing patients in clinical trials.
The company aims to commercialize the platform and related services by late 2018.
The SBIR Phase 1 award will go toward developing a test using immuno-PCR technology to detect toxins in medical marijuana.
The company is working with the University of Florida Health Cancer Center to validate its RadTox QuantiDNA test as a monitor of cfDNA in patient plasma.
The company has received grant funding for diagnostic development projects, and is also seeking its first pharma service customers to provide nearer-term revenue.
The funding will go towards developing the PathMap companion diagnostic technology, based on the firm's SnapPath platform.
Proposed increases to small business programs touch off fight between business and research groups, ScienceInsider reports.
The genetic screening firm validated the modifications with a Phase I SBIR grant from NIH and is seeking a Phase II grant to target critical protein domains.
The firm said the method could lead to more studies on the genetic determinants of disease for people of mixed or non-European ethnic backgrounds.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.